The race to be the next FDA Commissioner is becoming increasingly competitive, with candidates jostling for position and interested parties attempting to influence proceedings.
Alcan Packaging’s decision to close its packaging production facility in Nebraska, US, at a cost of 71 jobs, follows just weeks after parent company, Australian mining giant Rio Tinto, announced some 14,000 lay offs.
Portuguese contract manufacturer Hovione has emerged as the buyer for Pfizer’s production plant in Cork, Ireland, which was put on the block last year.
Serene has officially opened its offshore development centre in India, which will provide IT outsourcing services to support and complement its existing capabilities in the US.
The timely identification of contaminants in pharmaceutical manufacture can be critical to avoiding costly delays. While it is relatively straightforward to establish the composition of a contaminating particle, determining its origin in the manufacturing...
Valeant continues its spending spree with the $285m acquisition of California-based research dermatology specialist Dow Pharmaceutical Sciences (DPS), in a further bid to cement its market position.
Parexel has made a bold foray into the troublesome arena of stroke drug development via an alliance with Safe Implementation of Treatments in Stroke (SITS) International, an international network of clinical sites geared up to recruit stroke patients.
The MHRA has renewed its approval of Almac’s facility in North Carolina, bringing an end to a busy and successful four months of inspections at the clinical services group’s facilities.
Quadro Engineering has entered into a partnership to distribute Micro-Macinazione’s Jet-Mill products in the Americas, as well as launching its own API sifter.
The sales growth of generic drugs slowed considerably in 2008, dipping below the customary double digits to 3.6 per cent, according to a report by IMS Health.
The European Union’s long-awaited reform of pharmaceutical regulations known as the ‘pharmaceutical package’ was unveiled yesterday after months of consultation and debate.
Efforts to sure-up pharma track and trace rules and combat counterfeiting are a significant opportunity for specialist labelling firms, but the pace of change is proving to be a frustration, according to Domino Printing Sciences MD, Nigel Bond.
GlaxoSmithKline has gone into partnership with Indian contract manufacturing and development services company Kemwell to set up an R&D facility aimed at developing new oral healthcare products.
Although it is widely acknowledged that medical bracelets can be the difference between life and death, Australia’s Nanotechnology Victoria (NanoVic) has become the first to take the idea further with its insulin-delivering jewellery project.
One of Actavis’ Bulgarian production facilities is being bought out by the management, which will provide contract manufacturing services to the generic maker and other companies.
Demand for pharmaceutical manufacturing grade water in Europe shows no sign of drying up, according to a new study by industry analysts Frost & Sullivan.
Thermo Fisher Scientific has opened a clinical services facility in India, which will provide biopharma services to companies operating clinical trials.
Virginia’s Waste Control Board has challenged Merck to create different ways of achieving compliance with 2011 environmental standards, according to the Rocktown Weekly that is based in the state.
US contract research company MPI Research is laying off around 200 employees, but will still end the year with a higher headcount as it takes over two former Pfizer offices, according to local news reports.
Haemacure is calling for the International Court of Arbitration in Paris, France to force CSL Behring to make a $1.5m milestone payment that it believes is now due under a 2002 settlement related to firms’ disputed Hemaseel project.
KV Pharmaceuticals’ long-serving CEO Marc Hermelin has either been sacked or has retired, depending on which party’s version of events one believes, and is being replaced by David Vliet CEO of the company’s Ethex division on an interim basis.
Icon's recent $43.2m acquisition of New York-based Prevalere Life Sciences is the latest part of the firm's expansion in the US CRO market. Outsourcing-Pharma spoke with Icon's VP of bioanalytical development, Brian O'Dwyer, and Prevalere...
A UK judge has warned against the European Commission making rash changes following its report into big pharma blocking generics, arguing that it could damage development of new drugs.
India’s Bilcare has expanded its clinical trial materials business in its own market with the opening of new packaging and storage capacity at its facilities in Pune, India.
Contract research organisation PRA International has signed an agreement with fellow US firm Frontage Laboratories to expand the range of laboratory services it can offer to its clients.
Life sciences firm DSM has landed the contract to manufacture supplies of NicOx’ much vaunted anti-inflammatory agent naproxcinod and looks good for the long term deal.
Liverpool, UK-based biologics specialist Eden Biodesign has won three new manufacturing contracts - worth a total of £3m (€3.5m) – from clients in Europe and Asia.
Canadian contract manufacturer PharmEng International has managed to trim down its costs once again, but is still feeling the pain associated with the opening of its new facility in Sydney, Nova Scotia, and posted a loss of over C$8m (€5m).
Final guidance on the cooperative manufacture of licensed biologics has been issued by the FDA, which gives companies an outline of how to share responsibilities through the production process.
Icelandic generics firm Actavis plans to use Malta as a distribution hub for the supply of drugs to the emerging African pharmaceutical market, according to reports in the Maltese press.
A study in the Journal of the American Medical Association (JAMA) claiming there is no evidence that brandname cardiovascular drugs are superior to their generic counterparts, despite claims to the contrary.
Qatar and Egypt are to set up a new drug manufacturing plant at a facility in Qatar, according to BusinessIntelligence. The new facility will begin by producing soluble drugs for the emerging Qatari and Egyptian drug markets.
UK drug giant GSK is to shed 200 jobs at its manufacturing plant in Barnard Castle, County Durham to cut costs ahead of generic competition for products made at the facility, which include the anti-emetic Zofran (ondansentron).
Pantec Biosolutions has received CE marking for its painless laser epidermal system (P.L.E.A.S.E.), which it claims can facilitate transdermal delivery of high molecular weight drugs.
The latest research into the delivery of heparin was on display at this year’s AAPS, demonstrating the work that has been undertaken to improve administration methods.
Applied Cytometry (AC) hopes its VenturiOne v3 software, which is capable of processing 400 files in under 10 seconds, will win over drug developers looking to expedite large-scale laboratory analysis.
Quintiles Transnational has boosted its array of services for companies developing cancer drugs via the purchase of Illinois, US-based firm Targeted Molecular Diagnostics.
inVentive Health has been contracted to provide marketing and branding services for fellow US based generic injectables developer GeneraMedix, specifically focusing on the latter’s epoprostenol hypertension treatment.
News that US drugmaker Bristol-Myers Squibb (B-MS) is using its Foam Granulation Technology (FGT) to develop a second drug has worked formulation specialist Dow Wolff Cellulosics (DWC) into quite a lather.
Research into developing manufacturing methods to produce cheap antiretrovirals in Africa has been highlighted on World Aids Day by The Council for Scientific and Industrial Research (CSIR).
Domino Printing Sciences chose this year’s Emballage world packaging exhibition in Paris, France to showcase the new 5” printhead it has developed for its V300+ thermal transfer printer.
Competition commissioner Neelie Kroes said that some drugmakers operating in the EU are deliberately stalling the introduction of generics, costing European patients around €3bn ($3.87bn) a year more to buy medicines.
